Windward Bio Lists on Nasdaq, Shares Up 68% on Debut
Windward Bio Group AG (Nasdaq: WWB) began trading on Nov. 13, 2026, pricing its IPO at $17.00 per share and raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. Shares closed the first day up 68%, putting the market capitalization at roughly $1.69 billion — less than two years after the company's 2024 founding. The Basel-based, clinical-stage biotech develops ultra-long-acting antibodies for respiratory and dermatologic diseases.
Key figures
- Deal Value Usd
- 225000000
- Offering Price
- 17
- Shares Offered
- 10290000
- Series a
- $200 million (January 2025)
- Crossover financing
- $165 million (May 2026)
- Ipo premium day one
- 68%
- Market cap post debut
- 1690000000
- Concurrent private placement
- $50 million from Sanofi
- Total raised since inception
- $365 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.